DEVICE WITH COMPOSITIONS FOR DELIVERY TO THE LUNGS, THE ORAL MUCOSA AND THE BRAIN

Abstract

The present invention provides a passive inhaler for use in treating a number of diseases. The inventor has shown that the compositions comprised in the inhaler can be delivered to the lungs and to the brain in pharmacological relevant dosages, to treat a number of diseases in the lungs and the brain. Further, the inhaler is also able to deliver substances to the brain which may enhance transport across the blood brain barrier.

Claims

1. A passive inhaler device comprising a pharmaceutical composition and a carrier, the pharmaceutical comprising one or more of: cannabidiol, or a variant or a derivative thereof, THC, such as delta-9-THC or such as delta-8-THC or both, or a variant or a derivative thereof, any one of Ibuprofen, Paracetamol or an opioid, such as Fentanyl, and any one of caffeine, a terpene, such as a mono-, di-, or tri-terpene, and/or a tobacco leaf extract and, where in the inhaler is for delivery of the composition as a gas or a vapor.

2-7. (canceled)

8. The passive inhaler of claim 1, wherein the carrier is any one of terpenes derived from Cannabis, or total terpene extract from Cannabis plants, terpenes from coffe or cocoa. Mint, Eukalyptus oil, Citrus oil, tobacco extracts of Virginia, Burley, Caquito, Nicaragua etc., Anis oil, propylene glycol, ethanol, water, oxygen, nitrogen, normal air, sodium chloride, peppermint oil, or a terpene selected from the following list of borneol, camphor, β-caryophyllene, caryophyllene oxide, 1,8-Cineole, citral, Delta3Carene, geraniol, indomethacin, limonene, linalool, linalyl acetate, β-myrcene, myrcenol, I-menthol, menthone, neomenthol, nerol, nerolidol, α-pinene, peppermint oil, Pulegone, phytol, Terpineol, Terpinen-4-ol, thymohydroquinone, thymol, thymoquinone.

9. (canceled)

10. The passive inhaler device of claim 1, wherein the inhaler is not heated.

11. The passive inhaler device of claim 1, wherein the inhaler is not heated above any one of 60, 70, 80, or 90 degrees Celsius, or wherein the inhaler is not heated above any one of 140 degrees Celsius, such as above 150 degrees Celsius, such as above 160 degrees Celsius, such as above 170 degrees Celsius or above 180 degrees Celsius.

12-13. (canceled)

14. A passive inhaler of claim 1, wherein the composition comprises cannabidiol or a variant or a derivative thereof in a dosage within a range selected from the ranges of from 0.1 mg to 50 mg, such as from 0.1 mg to 40 mg, such as from 0.1 mg to 30 mg, such as from 0.1 mg to 20 mg, such as from 0.1 mg to 15 mg, such as from 0.1 to 10 mg, such as from 0.5 mg to 10 mg, such as from 1 mg to 10 mg.

15. A passive inhaler of claim 1, wherein the inhaler deliver the composition as a gas, or a vapor which is inhaled and wherein from 1 to 25%, such as from 1 to 20%, such as from 1 to 15%, such as from 5 to 15% of the dose present in the inhalator is delivered to the oral mucosa or to the lungs, when used continuously over a period of 1 to 6 hours, such as from 2 to 6 hours, such as from 1 to 4 hours such as from 1 to 3 hours.

16-17. (canceled)

18. A passive inhaler of claim 1, wherein the composition comprises THC:CBD in a 1:1 w/w ratio, such as in a 1:2 ratio, such as in a 1:3 ratio, such as in a 1:4 ratio, such as in a 1:5 ratio, such as in a 1:6 ratio, such as in a 1:7 ratio, such as in a 1:8 ratio, such as in a 1:9 ratio, such as in a 1:10 ratio, or CBD:THC in a 1:1 w/w ratio, such as in a 1:2 ratio, such as in a 1:3 ratio, such as in a 1:4 ratio, such as in a 1:5 ratio, such as in a 1:6 ratio, such as in a 1:7 ratio, such as in a 1:8 ratio, such as in a 1:9 ratio, such as in a 1:10 ratio.

19. A passive inhaler of claim 1, wherein the inhaler is made for treatment, prevention or alleviation of a lung disease with an inflammatory element, and/or the inhaler made for treatment, prevention, or alleviation of lung inflammation, and/or the inhaler is made for prophylaxis, treatment, prevention, or alleviation of a lunch disease such as any one of acute lung injury, Chronic Obstructive Pulmonary Disorder, such as any one of chronic bronchitis, emphysema and chronic obstructive airways disease, and/or the inhaler is made for treatment, prevention, or alleviation of a symptom of an inflammatory lung disease, and/or the inhaler is made for treatment, prevention, or alleviation of lung inflammation caused by any one of smoking, passive smoking, fumes, air pollution, dust and chemicals including grains, isocyanates, cadmium and coal dust, and/or the inhaler is made for treatment, prevention, or alleviation of lung inflammation by improving any one of the symptoms of breathlessness, persistent cough with phlegm, frequent chest infections, or wheezing.

20-24. (canceled)

25. A passive inhaler of claim 1, wherein the inhaler is made for treatment, prevention or alleviation of lung cancer, cancer in the oral cavity, head and neck cancer or cancer in the CNS.

26. A passive inhaler of claim 1, wherein the lung cancer is any one selected from the list of small cell lung cancer and non-small cell lung cancer the lung cancer is nonsmall cell lung cancer of any one of adenocarcinoma, squamous cell carcinoma or large cell carcinoma, and/or the lung cancer is nonsmall cell lung cancer in any one of stages I, II, III or IV, and/or wherein the cancer is small cell lung cancer in the limited stage, and/or wherein the cancer in the CNS is glioma or metastases of a cancer selected from the list of Lung cancer, breast cancer, genitourinary tract cancers, osteosarcoma, melanoma, head and neck cancer, neuroblastoma, gastrointestinal cancers, colorectal carcinoma, pancreatic carcinoma and lymphoma, and/or the composition is for use in combination with radiation therapy and/or chemotherapy.

27-31. (canceled)

32. A passive inhaler of claim 1, wherein the inhaler is for use as an anti-emetic in the treatment, prevention or alleviation of a condition selected from motion sickness, side effects of opioid analgesics, side effects of general anaesthetics, side effects of chemotherapy, severe cases of gasttroenteritis and morning sickness, or is for use in treatment, prevention or alleviation of any one of the conditions selected from the list of psychosis, anxiety, depression, schizophrenia, and epilepsy.

33. (canceled)

34. A passive inhaler of claim 1, wherein the inhaler is for use in treatment, prevention or alleviation of pain, such as any one of neuropatic pain, nociceptive pain, psychogenic pain, phantom limb pain, post herpetic neuralgia and complex regional pain syndrome.

35. A passive inhaler of claim 1, wherein the pain is caused by multiple sclerosis.

36. A passive inhaler of claim 1, wherein the inhaler is made for treatment, prevention or alleviation of a neurodegenerative disease.

37. A passive inhaler of claim 14, wherein the neurodegenerative disease is selected from the list of anyone of a plaque related disorder of the CNS, such as parkinsons disease, alzheimers disease, transmissible spongiform encephalopathy, bovine spongiform encephalopathy, huntingtons disease, Familial amyloid polyneuropathy, Finnish amyloidosis, Lattice corneal dystrophy, cerebral amyloid angiopathy, cerebral amyloid angiopathy Icelandic type.

38. (canceled)

39. A passive inhaler of claim 1, wherein the inhaler is made for increasing the transport of substances across the blood brain barrier.

40. A method of prophylaxis, treatment, prevention or alleviation of any one of the symptoms or diseases or conditions of any one of claim 8, using any one of the passive inhalers comprising compositions of claim 1.

41. (canceled)

42. Use of a method of claim 1 and/or a passive inhaler according to claim 1 in a method where the patient at least one time per day for 1-6 hours administers the compositions via a passive inhaler, by continued inhaling of air pulled through the device, so that for each breath of air taken into the lungs, air from a puff is dragged into the lungs with the inhaled air.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0221] Delivery and improved device.

[0222] In FIG. 1. Drawings show a VAVE Device with mouthpiece before the pinn/plounger (F) is pushed into the tube.

[0223] The one drawing (AA-1) show the device from outsite/showing the look and outer surfaces.

[0224] The one drawing (AA-2) show the device as a cut longitude through the device, open look, insite the device, turned 45 degrees to also show the mouthpiece part insite (see E-10)

[0225] In FIG. 2. Drawings show a VAVE Device with CAP (see detail B-100 and CAP (27)) and mouthpiece (see detailE-100) after the pinn/plounger (F) is pushed into the tube.

[0226] The one drawing (BB-1) show the device as a cut longitude through the device, open look, insite the device. (See counter and batterie, E.100)

[0227] The one drawing (BB-2) show the device as a cut longitude through the device, open look, insite the device, turned 45 degrees to also show the mouthpiece part insite in turned angle.

DETAILED DESCRIPTION OF THE INVENTION

[0228] The compositions of the present invention, for delivery via the nasal passage to the brain, may be delivered by various means known in the art, to provide the composition in a form which will be absorbed through the membranes in the back of the nose or the oral mucosa. In some embodiments, the passive inhaler device of the invention is anyone of the devices described below, or in WO2011/107104, or similar to those.

[0229] In one embodiment, such delivery may be by use of a device similar to that disclosed in WO2011/107104 (WO2011/107104 included by reference), in which 3 balls separate carrier from the active pharmaceutical ingredient (API). The present invention further provides a device which is improved in comparison to the device disclosed in WO2011107104. This improved device provides means to increase availability of the carrier, and to avoid carrier escaping the device if the user suck from the wrong end of the device, as well as means to avoid escape of material such as API or tobacco and/or marihuanna leaves etc. from the device in the end at which the user puffs from.

[0230] In one embodiment, a hard porous plastic (or similar) filter (A-100) is placed between the ball and the pin shaped release device. This filter will prevent escape of the carrier or other substance from the device, and will be able to absorb the carrier, and thereby, due to the increased exposure area, provide increased evaporation of the carrier. The increased evaporation of carrier will allow an increased efficiency of the delivery of substances from the device. The pore size may be varied to increase the resistance, or to increase or decrease the evaporation of the absorbed substance. Further, the hardness of the filter may be adjusted in order to avoid penetration by the release device. In one embodiment, the filter is attached to the release device, or is built into the release device, or the release device is a hard filter.

[0231] The filter (A-100) may in some embodiments be of a hardness which allow the inhaler to be activated.

[0232] In some embodiments, the filter (A-100) may be between 1 mm and 40 mm long.

[0233] In some embodiments, the filter (A-100) may have a pore size of between 0.01 micrometer and 10 micrometer. Produced with groves to regulate airflow and flowdrop.

[0234] In one embodiment, the device may comprise a porous or acetate filter (D) in the inhalation part, in order to prevent materials to escape from the inhalation device. This porous filter may be integrated in the central air passage of the existing barrier, e.g. star shaped barrier in the inhalation part. The porous filter (D) may be separate from the barrier.

[0235] The filter (D) may be between 1 mm and 20 mm long.

[0236] In some embodiments, it is preferred that there also is an increased area at which the carrier may pick up the API. This may be achieved by making the ball in the inhalation part smaller than the ball in the middle. In this way, the device may be designed to allow passage of the API past the ball, and to be absorbed by the filter (D-100). When the carrier passes through the first compartment and the filter (D-100), it will take up the API with increased efficiency. This filter (D-100) may in one non limiting embodiment consist of a normal acetate filter.

[0237] This improved device allows for improved efficacy of delivery, by higher concentration of API and carrier in the inhaled air from the device, as well as avoidance of escape of fluids and materials from the device.

[0238] It is important that the material of which the filters are made will not absorb the substances comprised in the device, such as the carriers and the API. It is also important that the filters have a pore size that allows air to be readily puffed through the filter by the user. Also, the filter material must be of a kind that will not release unwanted compounds from the filter material during use.

[0239] In non-limiting example the filter (A-100) and/or filter (D-100) may be made of polypropylene (PP) or polyurethane (PUR), or the like.

[0240] In one embodiment, a porous filter may also be placed between the balls, to create distance between the balls during production process and activation process and for the purpose separating the API and the carriers after activation.

[0241] The improvements in the device may also be described as follows:

[0242] (A-100): Hard PUR/PP etc. Stopfilter (A-100) Dose controle, Airflow and flowdrop improvement:

[0243] The hard PUR filter, (A-100), between the last inserted ball and the pin/plounger(F-100), enlarges the surface of the carriers and absorbing the carriers while moving the plounger(F-100) into the device for activation. Its function is also to stop liquids floating from the device and to keep the separation of the substances after activation. The function of this filter is also to bring possibility for the consumer to puff from both points of the device, without sucking the liquid extracts/substances into the mouth, as if this was a straw.

[0244] The function of this filter is also to push the 3 sealing bodies and the substances between these bodies into the first compartment, without collapsing, in a way, to stay partly in the second compartment partly in the first compartment or between these two compartments, after the activation process. This is to assure the use of the expanded area that the substances are vaporizing from and to controle the liquids in the device to stay away from the plounger point (F-100), opposite the mouthpiece point (E-10) and (E-100).

[0245] DETAIL: (B) & (C) CAP improvement, dose controle:

[0246] A solution with the cap(27). DETAIL B, added to open for solutions (C-10) that can bring different dosing controlling abilities to this improved device, such as electronic counters, electronic blinking lights, that can be in green turning to red, after a number of puffs of the right pressure, delivering the fixed needed dose per puff, depending on the nature of API that this device delivers.

[0247] Cap (27), that can have the feature incorporated Heat-flaps:on/off &battery (C-100), connected with the technology in the mouthpiece and incorporated technology with light(s) or whistle(s) to bring signals to the consumer when to stop further intake, after receiving full dose.

[0248] Accessories can make devices look in the way, that consumers need, to “take the medicine” The cap solution is a way to improve the device in a way, that brings the consumer into a more acceptable lifestyle, while consuming the needed treatment.

[0249] The cap solution improves the feasibility of activating the device more easy. It also shows from where to puff, having the mouthpiece in the one point.

[0250] The cap can be designed in different designs and colors and materials, as long as it is designed to hold the inhaler inside, in a way to provide air passing through, when inserted and activated.

[0251] (D-100) Soft acetate etc. improvement:

[0252] The soft filter, (D-100), to be inserted in the position in the inhalation part of the device. This filter avoids particles to pass through the star hole and absorbes the API to enlarge the surface for volatile “delivering” the liquid API as a gas, with or without being picked up by volatile carriers, that is fysically moved by air containing water vapor, nitrogen, oxygen, argon, carbon dioxide, neon, helium, krypton, hydrogen, xenon and different particles from the area, that can be particles from environmental character or pollution, like in cities we find high consentration of diesel combustion, charcoal combustion, smoking particles, combustion particles from chimneys etc. airborne latex allergens, allergenic proteins etc. and these particles can be from nature like hay fever from grass, pollinosis from pollens of any plant, animal dander etc.

[0253] This filter can be produced from supplyer directly in connection with different fermented and cutted tobacco or marihuana etc. leaves together with the starhole filter.

[0254] (G-10).

[0255] Mouthpice improvement:

[0256] The mouthpiece, (E-10) and nose/mouth pice (E-100), invented provides a stop solution barre, for the purpose to avoid ricecorns, different plant leaves etc to pass through the star hole in the filter of the device/improved inhaler, in a way, that the particle is dirigated to stay in the mouthpiece.

[0257] This mouthpiece can be constructed including electronic counter, figures to provide the consumer with informations regarding the dosage, passing through the device. This electronic counter technology can be separated from or connected with the Cap (27), that can have the feature incorporated battery, connected with the technology in the mouthpiece and incorporated technology with light(s) or whistle to bring signals to the consumer when to stop further intake, after receiving full dose.

[0258] This mouthpiece can also be constructed to be used for the purpose delivering the vapor nasally. (see E-100)

[0259] This way its designed as a double tube “nosemouthpiece” (E-100) added to this inventions improved device, and can be a part of this invention.

[0260] Endpoints and Markers

[0261] Effects of the treatments presented in the invention relating to lung inflammation, may be in non limiting example measured as improvements of various disease markers. In non-limiting example, such markers may include any one of an inflammation marker selected from the list of C-reactive protein (CRP), soluble tumour necfosis factor-receptor (TNFR-1), osteoprotegrin (OPG) and monocyte chemoattractant protein-4 (MCP4) (Eagan et al. 2010 European Respiratory Journal vol 35 no 3 p 540-548). Other objective indications of improvement, such as improvement in a disease symptom may also be taken as measurement for effect. One effect by which effect may be measured is general well being, mucus coughing coloured with e.g. tar particles. Improvement in ease of breathing.

[0262] Effects of the treatments presented in the invention relating to lung cancer or cancer in the CNS, may in non limiting example be measured as improvements of various disease markers. In non limiting example, this may be proliferation arrest, prevention of spreading of disease into other tissues, shrinking of tumor mass.

[0263] Effects of the treatments presented in the invention relating to epilepsy, may in non limiting example be measured by reduction in severity of attacks or fewer attacks.

[0264] Effects of the treatments presented in the invention relating to the use of the passive inhaler as an anti-emetic, may in non limiting example be measured by reduction in vomiting, or in the sensation of nauseaness.

[0265] Effects of the treatments presented in the invention relating to the use of the passive inhaler to treat anxiety, depression or psychosis, may be measured by a reduction in the symptoms of those diseases.

[0266] Effects of the treatments presented in the invention relating to use of the passive inhaler to treat neurodegenerative diseases, may be measured by observing a slowing down of the decline in neurological function.

EXAMPLES

Example 1

[0267] The compositions and methods of the invention will be tested in relevant animal models of inflammatory lung diseases, including models of acute lung injury and COPD.

[0268] Various dosages of CBD will be delivered to the lungs by use of passive inhaler devices comprising different dosages of CBD and a carrier to identify the optimal dosage range.

Example 2

[0269] In some applications, nicotine may be used in the inhaler. Nicotine may be delivered in three forms with tobacco flavours:

[0270] A: As dried fermented tobacco leaves in cut form (this form will provide a stimulus to the brain similar to that of natural tobacco flavours as seen when smoking)

[0271] B: As heat (247 degree Celcius) or high pressure destilled extract made by a 7 phase distillation process, wherein the extract comprises nicotine and possibly some tobacco flavours.

[0272] C: As a blended mass of tobacco leaves, extracted by nut oil, tasteless oil or propylene glycol. In some instances it may be washed with CO2 or ethanol in the aromaextration process. The composition is mixed with the composition of B), and leaf parts are removed by pouring through a cloth or the like. The resulting fluid will be uniform and volatile and able to release its natural tobacco flavours

Example 3

[0273] CBD extraction from Cannabis plants is done similar to nicotine extraction from tobacco as described in example 2.

[0274] CBD is extracted at 250 degrees Celcius.

[0275] Cannabidiol (CBD) has a boiling point of: 160-180 degrees C./320-356 degrees Fahrenheit

[0276] CBD may also be extracted by other methods, such as CO2 extraction, Ethanol or olive oil extraction: [0277] CO2 extraction. The supercritical (or subcritical) CO2 method uses carbon dioxide under high pressure and extremely low temperatures to isolate, preserve, and maintain the purity of the medicinal oil. This process requires expensive equipment and a steep operational learning curve. But, when done well the end product is safe, potent, and free of chlorophyll. [0278] Ethanol. High grade grain alcohol can be used to create high quality cannabis oil appropriate for vape pen cartridges (E-cigarettes using heating) and many other products. But this extraction method destroys the plant waxes, which may have health benefits that are favored by some product-makers. [0279] Olive oil. Extra virgin or otherwise, olive oil can also be used to extract cannabis oil. Dr. Arno Hazekamp, director of phytochemical research at Bedrocan BV, which supplies medical cannabis for the Dutch Health Ministry, reports this method is both safe and inexpensive, “You won't blow yourself up making cannabis-infused olive oil.” Cannabis-infused olive oil—whether CBD-rich or THC-dominant—is however perishable and should be stored in a cool, dark place.

[0280] Properties: Anxiolytic, Analgesic, Antipsychotic, Antiinflammatory,

[0281] Antioxidant,

[0282] Antispasmodic

[0283] Properties of other cannabis compounds:

[0284] Cannabinol (CBN)

[0285] Boiling point: 185° C./365 degree Fahrenheit

[0286] Properties: Oxidation, breakdown, product, Sedative, Antibiotic

[0287] Cannabichromene (CBC)

[0288] Boiling point: 220° C./428 degree Fahrenheit

[0289] Properties: Antiinflammatory, Antibiotic, Antifungal

[0290] Δ-8-tetrahydrocannabinol (Δ-8-THC)

[0291] Boiling point: 175-178° C./347-352.4 degree Fahrenheit

[0292] Properties: Resembles Δ-9-THC, Less psychoactive, More stable Antiemetic

[0293] Tetrahydrocannabivarin (THCV)

[0294] Boiling point: <220° C./<428 degree Fahrenheit

[0295] Properties: Analgesic, Euphoriant

Example 4

[0296] In some instances, it will be advantageous to supplement treatment of the present invention with systemic treatment with CBD. For this purpose CBD in capsule form up to a maximum of 100-200 mg daily, preferably 100 mg daily, may be administered.

[0297] CBD in capsule form, may be delivered via the gastrointestinal tract.

Example 5

[0298] 10 COPD patients were given a device comprising 8.6 mg CBD and peppermint oil to a total of about 75 mg.

[0299] The patients took 200 puffs in about 4-6 hours, wherein the patients took one puff through the device and included the air from that one puff in each breath of air that was taken into the lungs. This procedure was continued for 4-6 hours.

[0300] Result: the patients felt an improved well being, they coughed up black mucus, and felt an improved ease of breathing.

Example 6

[0301] 10 COPD patients will be given a device comprising 8.6 mg CBD and a 50:50 mixture of peppermint oil and total cannabis sativa terpene extract to a total of about 75 mg.

[0302] The patients will take 200 puffs in about 4-6 hours, wherein the patients took one puff through the device and included the air from that one puff in each breath of air that was taken into the lungs. This procedure was continued for 4-6 hours.

[0303] Some patients will be given two times 200 puffs per day, and some will be given only 200 puffs per day.

[0304] Some patients will as a control be given the CBD/peppermint oil device of example 5.

Example 7

[0305] A patient suffering from multiple sclerosis experiencing continuous pain, which he normally only can treat by smoking of cannabis, which has the side effect of making him constantly under influence by the drug, and thereby being mentally sedated in addition to the effect on the pain. The patient does not respond to CBD gel capsules when taken orally, and is thus a non-responder to oral CBD.

[0306] The patient tested the passive inhaler devices of the invention loaded with three different compositions: [0307] 1) Negative control only loaded with peppermint oil as a carrier. [0308] 2) Positive loaded with CBD and peppermint oil, wherein the concentration of the CBD initially was 61%, and after mixing with carrier (peppermint oil), the final concentration of CBD was 30% by weight. [0309] 3) Positive loaded with CBD (31%) and carrier (peppermint oil), the final concentration of CBD was 15% by weight.

[0310] The patient experienced severe pain in the legs and feet, and the sensation of pain was not influenced by inhaling the negative control after about 15 minutes of puffing on device number 1. The patient however responded to both inhaler number 2 and 3. His response to inhaler number 3 was partial, as he after puffing on device number 3 for about 12 minutes, he still experienced moderate pain, but described the effect as good. Device number 2 with 30% CBD by weight had the best effect, it removed so much pain that the patient did no longer have to use energy to control his pain. This effect appeared after about 10 minutes, and lasted for about 16 minutes after which he had to puff again. This allowed him to walk about in the room without feeling pain.

[0311] The patient had not smoked cannabis for 3 days before the testing of the devices. He explained that it was a relief not to feel influenced by the cannabis, as the devices number 2 and 3 gave the pain relief without affecting him otherwise (no psychoactive effects).

EMBODIMENTS

[0312] 1. A composition comprising cannabidiol or a variant or a derivative thereof, for delivery as anyone of in independent embodiments: a gas, or a vapor or a mist or an aerosol, for inhalation into the lungs, for use as a pharmaceutical, wherein the gas, or a vapor or a mist or an aerosol is not made by heating. [0313] 2. A composition according to embodiment 1, wherein the gas, or vapor or mist or aerosol is not made by heating above any one of 60, 70, 80, or 90 degrees celcius. [0314] 3. A composition according to embodiment 1, wherein the gas, or vapor or mist or aerosol is not made by heating above any one of 140° C., such as above 150° C., such as above 160° C., such as above 170° C. or above 180° C. [0315] 4. A composition according to any one of embodiments 1 to 3, wherein the composition is delivered by use of a passive inhalator. [0316] 5. A composition according to anyone of embodiments 1 to 4, wherein the composition is for delivery as a gas or a vapor. [0317] 6. A composition according to any one of embodiments 1 to 5, wherein the composition comprises cannabidiol or a variant or a derivative thereof in a dosage within a range selected from the ranges of from 0.1 mg to 50 mg, such as from 0.1 mg to 40 mg, such as from 0.1 mg to 30 mg, such as from 0.1 mg to 20 mg, such as from 0.1 mg to 15 mg, such as from 0.1 to 10 mg, such as from 0.5 mg to 10 mg, such as from 1 mg to 10 mg. [0318] 7. A composition according to any one of embodiments 1 to 6, wherein the composition is delivered by use of a passive inhalator, and wherein the gas, or a vapor or a mist or an aerosol which is inhaled delivers from 1 to 25%, such as from 1 to 20%, such as from 1 to 15%, such as from 5 to 15% of the dose present in the inhalator when used continuously over a period of 1 to 6 hours, such as from 2 to 6 hours, such as from 1 to 4 hours such as from 1 to 3 hours. [0319] 8. A composition according to any one of embodiments 1 to 7, wherein the composition further comprises a carrier, such as in non limiting example a peppermintoil, or in another non limiting example a vegetable oil with a flavour [0320] 9. A composition according to any one of embodiments 1 to 8, wherein the content of cannabidiol or a variant or a derivative thereof by weight percent to total weight of the composition is within the range of from 0.01% to 30% cannabidiol or a variant or a derivative thereof. [0321] 10. A composition according to any one of embodiments 1 to 9, wherein the composition further comprises THC, such as delta-9-THC or such as delta-8-THC or both. [0322] 11. A composition according to embodiment 10, wherein the composition comprises THC:CBD in a 1:1 w/w ratio, such as in a 1:2 ratio, such as in a 1:3 ratio, such as in a 1:4 ratio, such as in a 1:5 ratio, such as in a 1:6 ratio, such as in a 1:7 ratio, such as in a 1:8 ratio, such as in a 1:9 ratio, such as in a 1:10 ratio. [0323] 12. A composition according to any one of embodiments 1 to 11, wherein the composition further comprises one or more of a terpene or terpenoid. [0324] 13. A composition according to embodiment 12, wherein the terpenoid is one or more selected from the list of total terpene extract from cannabis sativa, 1,8-cineole, d-limonene, β-myrcene, myrcenol, nerol, α-pinene, linalool, (3-caryophyllene, indomethacin, caryophyllene oxide, nerolidol, peppermint oil, 1-menthol, menthone, neomenthol, thymohydroquinone, thymol, thymoquinone, phytol, borneol, camphor, citral, geramol, farnesol and delta3Carene. [0325] 14. A composition according to embodiment 12, wherein the terpenoid is one or more selected from the list of total terpene extract from cannabis sativa, 1,8-cineole, d-limonene, β-myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol, phytol, borneol, citral, indomethacin and geramol. [0326] 15. A composition according to any one of embodiments 1 to 13, wherein the composition is made for treatment, prevention or alleviation of a lung disease with an inflammatory element. [0327] 16. A composition according to any one of embodiments 1 to 15, wherein the composition is made for treatment, prevention or alleviation of lung inflammation. [0328] 17. A composition according to any one of embodiments 1 to 16, wherein the composition is made for prophylaxis, treatment, prevention or alleviation of a lung disease such as any one of acute lung injury, Chronic Obstructive Pulmonary Disorder, such as any one of chronic bronchitis, emphysema and chronic obstructive airways disease. [0329] 18. A composition according to any one of embodiments 1 to 17, wherein the composition is made for treatment, prevention or alleviation of a symptom of an inflammatory lung disease. [0330] 19. A composition according to any one of embodiments 1 to 18, wherein the composition is made for treatment, prevention or alleviation of lung inflammation caused by any one of smoking, passive smoking, fumes, air pollution, dust and chemicals including grains, isocyanates, cadmium and coal dust. [0331] 20. A composition according to any one of embodiments 1 to 19, wherein the composition is made for treatment, prevention or alleviation of lung inflammation by improving any one of the symptoms of breathlessness, persistent cough with phlegm, frequent chest infections, or wheezing. [0332] 21. A composition according to any one of embodiments 1 to 12 and 14, wherein the composition is made for treatment, prevention or alleviation of lung cancer. [0333] 22. A composition according to embodiment 21, wherein the lung cancer is any one selected from the list of small cell lung cancer and nonsmall cell lung cancer. [0334] 23. A composition according to embodiments 21 or 22, wherein the lung cancer is nonsmall cell lung cancer of any one of types adenocarcinoma, squamous cell carcinoma or large cell carcinoma. [0335] 24. A composition according to anyone of embodiments 21 to 23, wherein the lung cancer is nonsmall cell lung cancer in any one of stages I, II, III or IV. [0336] 25. A composition according to embodiment 21 or 22, wherein the cancer is small cell lung cancer in the limited stage. [0337] 26. A composition according to any one of embodiments 21 to 25, wherein the composition is for use in combination with radiation therapy and/or chemotherapy. [0338] 27. A composition according to any one of embodiments 1 to 26, wherein the composition is made for use in combination with existing treatment for the conditions. [0339] 28. A passive inhaler comprising the composition according to any one of embodiments 1 to 27. [0340] 29. A method of prophylaxis, treatment, prevention or alleviation of any one of the symptoms or diseases or conditions of any one of embodiments 15 to 28, using any one of the methods and compositions of any one of embodiments 1 to 14. [0341] 30. In one embodiment, methods and compositions of any one of embodiments 1 to 29, are for use in combination with administration of CBD by other means than inhalation, such other means may in non limiting example be oral or rectal administration or injected or by slow release deposits. [0342] 31. In one embodiment, the methods and compositions according to the any one of the previous embodiments, are for use in a method where the patient at least one time per day for 1-6 hours administers the compositions via a passive inhaler, by continued inhaling of air pulled through the device, so that for each breath of air taken into the lungs, air from a puff is dragged into the lungs with the inhaled air. [0343] 32. In one embodiment, the compositions of the present invention comprises one or more of CBD or THC or a terpene or a derivative or variant of any of those as the active ingredient. [0344] 33. In one embodiment, the compositions of the present invention comprises THC and CBD or a derivative or variant of any one of those as the active ingredients. [0345] 34. In one embodiment, the compositions of the present invention and according to the previous embodiments comprises THC or a derivative or a variant thereof and a terpene as the active ingredients. [0346] 35. In one embodiment, the compositions of the present invention, comprises CBD or a derivative or a variant thereof and a terpene as the active ingredients [0347] 36. In one embodiment, the compositions of the present invention, comprises CBD and THC or derivatives or variants thereof, and a terpene or a terpene mix as the active ingredients. [0348] 37. In one embodiment according to anyone of the previous embodiments, CBD or THC or terpenes may be a raw extract of cannabis sativa. [0349] 38. In one embodiment according to embodiment 37, terpenes may be a total terpene distillate from cannabis sativa. [0350] 39. In one embodiment according to any one of the previous embodiments, CBD or THC or terpenes may be isolated from cannabis sativa, and may comprise trace amounts of other compounds, such that a CBD isolate may comprise trace amounts of THC and/or terpenes. [0351] 40. An improved inhalator (1) comprising a housing with at least a first compartment (30) and a second compartment (40), and including one or more substances, said second compartment (40) including at least one air entry port (50), said inhalator (1) having a first end (21) proximal to said first compartment (30) and a second end) proximal to said second compartment (40), an inhalation part 2 (27) being at said second end (22) and said second compartment (40) being for storing at least one substance and including in an inoperative state of said inhalator (1) 2,3 or more sealing bodies, if having, in sets of 3 sealing bodies, one in the center (65) as the largest and the other 2 sealing bodies (66a&b) smaller than the one in center (65), to provide the substances pass around the small sealing bodies while moved by the plounger (F) under pressure; to achieve separation of the substances after moving these from second compartment to first compartment, having the substances absorbed in the new invented filter (A) behind the last sealing body, and the other substances in the separated inner center pressed into the first compartment (30) for this substance to be absorbed in the other new invented filter (D). Arranged in a neighboring relationship (60), while sealed in the second compartment (40), each pair of neighboring bodies defining at least in part a sealed chamber (62) for containing a substance, said bodies (60) being movable together with said at least one substance from said second compartment (40) into said first compartment (30) to define an operative state of said inhalator (1) wherein said one or more substances are contained in said first compartment (30), whereby air entering through said air entry port (50) (F) and taking up, such as by evaporation, said at least one substance when contained in said first compartment (30) may be inhaled through said inhalation part 2 (27), characterized in a release device in said second compartment (40), said release device being for moving said bodies (60) into said first compartment and allowing said air to flow to said air entry port (50) in said operative state or to said air entry inhalation part 1 (27) at first end (21) characterized in that the inhalator further comprises one or more of a filter (A) is present between the one ball (66a.) and the pin/plounger (F) shaped release device, where the pin/plounger (F) can be a filter it selves, made by polyurethane plast (PUR), and/or between any one of the balls (60), and/or a filter (D) is present in the inhalation part of the device (21) first end inhalation part 1. (27) to controle airflow and flowdrop, depending at the length and porosity of this filter (D) and to obtain API for enlarging the surface to vaporize more effectively and to avoid particles passing through the starhole in the acetate star hole filter (G) placed near to (21) first end, where the users lips while puffing and as accessory a mouthpiece (E) to add to the improved inhaler with a stop barrier inside and a variety that provides a “nosemouth” pice (E) solution as a new design to be added to the improved inhaler, with or without a cap tube (B) to install the improved inhaler (1) into, bringing the possibility, together or solely with the mouthpiece (E), of adding dosing technology like (C) (E) counter electronic systems or blinking or changing coloured light from green to red, when enough puffs are provided via the improved inhaler.